Physicians' Academy for Cardiovascular Education

3 Challenges when targeting inflammation in residual CV risk

10' education - Mar. 29, 2022 - Prof. Filippo Crea, MD - Rome, Italy

Video navigation menu

  • From a working hypothesis in 1994 to clinical trials 00:22
  • Challenge 1: Identifying patients susceptible to beneficial effect of anti-inflammatory therapy: plaque fissure vs. erosion 04:49
  • Challenge 2: Balance of benefits vs. harm of anti-inflammatory therapies 10:08:
  • Challenge 3: Window of opportunity - plaque healing  11:42

Transcript

Show transcript

Educational information

This presentation by Filippo Crea is part of a series titled "Inflammation: The next therapeutic frontier in targeting cardiovascular risk". This series consists of an introduction, three lectures and a discussion in which four experts in this field will bring you up to date on the role of inflammation in atherosclerosis and how to translate findings from science and clinical trials into practice.

Faculty

Filippo Crea is editor-in-chief of the European Heart Journal and affiliated with the Catholic University of the Sacred Heart in Rome, Italy.

Disclosures

This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.

Funding

Funding for this educational program was provided by an unrestricted educational grant received from Novo Nordisk A/S.

View the slides of this presentation

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Share this page with your colleagues and friends: